Drug repurposing against coronavirus disease 2019 (COVID-19): A review

Journal of Pharmaceutical Analysis

Fangfang Huang¹  Qin Qiu²  Liao Cui³  Hui Luo⁴  Kaifeng Liu⁵  Yongqi Lan⁵  Lianxiang Luo⁶  Yuge Huang⁷  Xiaoling Li⁷ 

[1] Corresponding author. Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, 524023, Guangdong, China.;Marine Medical Research Institute of Zhanjiang, Zhanjiang, 524023, Guangdong, China;Animal Experiment Center, Guangdong Medical University, Zhanjiang, 524023, Guangdong, China;Department of Pediatrics, the Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524023, Guangdong, China;Graduate School, Guangdong Medical University, Zhanjiang, 524023, Guangdong, China;Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, 524023, Guangdong, China;The First Clinical College, Guangdong Medical University, Zhanjiang, 524023, Guangdong, China;

关键词: Drug repurposing;    COVID-19;    SARS-CoV-2;    Virtual screening;    3C-like protease;   

DOI  :  

来源: DOAJ

【 摘 要 】

Since December 2019, severe acute respiratory syndrome coronavirus 2 has been found to be the culprit in the coronavirus disease 2019 (COVID-19), causing a global pandemic. Despite the existence of many vaccine programs, the number of confirmed cases and fatalities due to COVID-19 is still increasing. Furthermore, a number of variants have been reported. Because of the absence of approved anti-coronavirus drugs, the treatment and management of COVID-19 has become a global challenge. Under these circumstances, drug repurposing is an effective method to identify candidate drugs with a shorter cycle of clinical trials. Here, we summarize the current status of the application of drug repurposing in COVID-19, including drug repurposing based on virtual computer screening, network pharmacology, and bioactivity, which may be a beneficial COVID-19 treatment.

【 授权许可】

Unknown